Tempo Therapeutics Secures Series A Financing to Advance Cutting-Edge Tissue Scaffold Products into Clinical Trials

SAN DIEGO, March 19, 2024 /PRNewswire/ — Tempo Therapeutics, Inc (“Tempo”) a leading innovator in tissue engineering and regenerative medicine, today announced the successful completion of its $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson &…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks